Aldeyra Therapeutics, Inc. (ALDX)
0.7373
-0.05
(-6.72%)
USD |
NASDAQ |
Oct 15, 16:00
0.752
+0.01
(+1.99%)
After-Hours: 20:00
Aldeyra Therapeutics Cash from Operations (TTM) : -22.02M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.02M |
| March 31, 2026 | -25.99M |
| December 31, 2025 | -33.35M |
| September 30, 2025 | -40.08M |
| June 30, 2025 | -41.04M |
| March 31, 2025 | -45.71M |
| December 31, 2024 | -43.21M |
| September 30, 2024 | -30.67M |
| June 30, 2024 | -30.72M |
| March 31, 2024 | -30.86M |
| December 31, 2023 | -30.33M |
| September 30, 2023 | -42.06M |
| June 30, 2023 | -46.61M |
| March 31, 2023 | -53.21M |
| December 31, 2022 | -56.64M |
| September 30, 2022 | -56.98M |
| June 30, 2022 | -52.84M |
| March 31, 2022 | -41.96M |
| December 31, 2021 | -42.56M |
| September 30, 2021 | -39.30M |
| June 30, 2021 | -37.10M |
| March 31, 2021 | -35.61M |
| December 31, 2020 | -37.49M |
| September 30, 2020 | -40.40M |
| Date | Value |
|---|---|
| June 30, 2020 | -42.08M |
| March 31, 2020 | -47.31M |
| December 31, 2019 | -44.98M |
| September 30, 2019 | -41.68M |
| June 30, 2019 | -41.50M |
| March 31, 2019 | -34.93M |
| December 31, 2018 | -29.86M |
| September 30, 2018 | -27.12M |
| June 30, 2018 | -24.09M |
| March 31, 2018 | -23.16M |
| December 31, 2017 | -19.39M |
| September 30, 2017 | -18.11M |
| June 30, 2017 | -16.91M |
| March 31, 2017 | -14.85M |
| December 31, 2016 | -15.15M |
| September 30, 2016 | -14.26M |
| June 30, 2016 | -13.64M |
| March 31, 2016 | -11.99M |
| December 31, 2015 | -9.348M |
| September 30, 2015 | -7.936M |
| June 30, 2015 | -6.263M |
| March 31, 2015 | -5.556M |
| December 31, 2014 | -4.776M |
| September 30, 2014 | -3.770M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -59.06M |
| Oncolytics Biotech, Inc. | -26.52M |
| Sangamo Therapeutics, Inc. | -90.34M |
| Sarepta Therapeutics, Inc. | 93.95M |
| Anixa Biosciences, Inc. | -7.376M |